Cargando…

The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type

BACKGROUND: Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless...

Descripción completa

Detalles Bibliográficos
Autores principales: Amin, Saber, Baine, Michael, Meza, Jane, Lin, Chi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033704/
https://www.ncbi.nlm.nih.gov/pubmed/33836694
http://dx.doi.org/10.1186/s12885-021-08129-4
_version_ 1783676450330640384
author Amin, Saber
Baine, Michael
Meza, Jane
Lin, Chi
author_facet Amin, Saber
Baine, Michael
Meza, Jane
Lin, Chi
author_sort Amin, Saber
collection PubMed
description BACKGROUND: Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site. METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The Cox proportional hazard model adjusted for age at diagnosis, race, sex, place of living, income, education, primary tumor type, year of diagnosis, chemotherapy, radiation therapy (RT), and surgery of the primary cancer site was used to determine treatment facility-associated hazard ratios (HR) for survival. Overall survival was the primary outcome, which was analyzed with multivariable Cox proportional hazards regression modeling. RESULTS: A total of 93,633 patients were analyzed, among whom 31,579/93,633 (34.09%) were treated at academic centers. Based on the log-rank analysis, patients who received treatment at an academic facility had significantly improved OS (median OS: 6.18, CI: 6.05–6.31 vs. 4.57, CI: 4.50–4.63 months; p < 0.001) compared to patients who were treated at non-academic facilities. In the multivariable Cox regression analysis, receiving treatment at an academic facility was associated with significantly improved OS (HR: 0.85, CI: 0.84–0.87; p < 0.001) compared to non-academic facility. CONCLUSIONS: In this extensive analysis of the NCDB, receiving treatment at academic centers was associated with significantly improved OS compared to treatment at non-academic centers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08129-4.
format Online
Article
Text
id pubmed-8033704
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80337042021-04-09 The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type Amin, Saber Baine, Michael Meza, Jane Lin, Chi BMC Cancer Research Article BACKGROUND: Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site. METHODS: This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The Cox proportional hazard model adjusted for age at diagnosis, race, sex, place of living, income, education, primary tumor type, year of diagnosis, chemotherapy, radiation therapy (RT), and surgery of the primary cancer site was used to determine treatment facility-associated hazard ratios (HR) for survival. Overall survival was the primary outcome, which was analyzed with multivariable Cox proportional hazards regression modeling. RESULTS: A total of 93,633 patients were analyzed, among whom 31,579/93,633 (34.09%) were treated at academic centers. Based on the log-rank analysis, patients who received treatment at an academic facility had significantly improved OS (median OS: 6.18, CI: 6.05–6.31 vs. 4.57, CI: 4.50–4.63 months; p < 0.001) compared to patients who were treated at non-academic facilities. In the multivariable Cox regression analysis, receiving treatment at an academic facility was associated with significantly improved OS (HR: 0.85, CI: 0.84–0.87; p < 0.001) compared to non-academic facility. CONCLUSIONS: In this extensive analysis of the NCDB, receiving treatment at academic centers was associated with significantly improved OS compared to treatment at non-academic centers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08129-4. BioMed Central 2021-04-09 /pmc/articles/PMC8033704/ /pubmed/33836694 http://dx.doi.org/10.1186/s12885-021-08129-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Amin, Saber
Baine, Michael
Meza, Jane
Lin, Chi
The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
title The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
title_full The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
title_fullStr The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
title_full_unstemmed The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
title_short The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
title_sort impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033704/
https://www.ncbi.nlm.nih.gov/pubmed/33836694
http://dx.doi.org/10.1186/s12885-021-08129-4
work_keys_str_mv AT aminsaber theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype
AT bainemichael theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype
AT mezajane theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype
AT linchi theimpactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype
AT aminsaber impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype
AT bainemichael impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype
AT mezajane impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype
AT linchi impactoftreatmentfacilitytypeonthesurvivalofbrainmetastasespatientsregardlessoftheprimarycancertype